Integra LifeSciences Holdings - Asset Resilience Ratio
Integra LifeSciences Holdings (IART) has an Asset Resilience Ratio of 0.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Integra LifeSciences Holdings's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Integra LifeSciences Holdings's Asset Resilience Ratio has changed over time. See net asset quality index of Integra LifeSciences Holdings to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Integra LifeSciences Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Integra LifeSciences Holdings.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $28.69 Million | 0.8% |
| Total Liquid Assets | $28.69 Million | 0.80% |
Asset Resilience Insights
- Limited Liquidity: Integra LifeSciences Holdings maintains only 0.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Integra LifeSciences Holdings Industry Peers by Asset Resilience Ratio
Compare Integra LifeSciences Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Integra LifeSciences Holdings (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Integra LifeSciences Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.80% | $28.69 Million | $3.60 Billion | +0.12pp |
| 2024-12-31 | 0.67% | $27.19 Million | $4.04 Billion | -0.19pp |
| 2023-12-31 | 0.86% | $32.69 Million | $3.78 Billion | +0.44pp |
| 2022-12-31 | 0.43% | $16.68 Million | $3.89 Billion | +0.43pp |
| 2019-12-31 | 0.00% | $12.00K | $3.30 Billion | -0.15pp |
| 2018-12-31 | 0.15% | $4.65 Million | $3.11 Billion | +0.10pp |
| 2017-12-31 | 0.05% | $1.52 Million | $3.21 Billion | +0.03pp |
| 2016-12-31 | 0.01% | $242.00K | $1.81 Billion | -0.22pp |
| 2015-12-31 | 0.23% | $4.07 Million | $1.77 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $1.58 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $1.20 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.16 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.14 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $1.02 Billion | -- |
| 2005-12-31 | 17.91% | $80.33 Million | $448.43 Million | +11.14pp |
| 2004-12-31 | 6.78% | $30.95 Million | $456.71 Million | -0.39pp |
| 2003-12-31 | 7.17% | $29.57 Million | $412.53 Million | -12.96pp |
| 2002-12-31 | 20.13% | $55.28 Million | $274.67 Million | +10.38pp |
| 2001-12-31 | 9.75% | $22.18 Million | $227.59 Million | +8.53pp |
| 2000-12-31 | 1.22% | $1.05 Million | $86.51 Million | -5.27pp |
| 1999-12-31 | 6.49% | $4.30 Million | $66.30 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more